Johnson & Johnson Stock Dips Amid Strong ICOTYDE Data

Johnson & Johnson's stock saw a slight dip on October 2, 2026, closing at USD 256.03 on the NYSE, down 1.02% from the previous day. However, the company provided a boost with positive ICOTYDE results, showing a 70% clear or almost clear skin rate at Week 112. The Phase 3 ICONIC-TOTAL study, which delivers two-year data, revealed complete site-specific clearance for 60% of patients with scalp psoriasis and 89% with genital psoriasis at Week 112. Additionally, the overall clearance rate improved from 57% at Week 16 to 70% at Week 112.

The data is crucial as Johnson & Johnson aims to build newer medicines to counter pressure on established products like Stelara. ICOTYDE, an oral IL-23 receptor peptide approved for moderate-to-severe plaque psoriasis, demonstrated consistent safety findings through Week 112. The company's second-quarter revenue for 2026 reached USD 25.31 billion, up 6.6% year over year, surpassing the consensus estimate of USD 25.06 billion. Adjusted EPS was USD 2.90, beating the consensus of USD 2.84.

MarketBeat reports a Moderate Buy consensus for Johnson & Johnson, with an average price target of USD 275.87, 7.7% above the current stock price. Analysts highlight Stelara biosimilar competition as a key near-term pressure, while ICOTYDE and other newer launches provide growth counterweights. The stock closed 8.9% below its 52-week high of USD 281.07 but 39.9% above its 52-week low of USD 182.94, with a market capitalization of USD 617.0 billion.

The upcoming third-quarter results on October 13, 2026, will be a critical checkpoint for the company's valuation. The fiscal 2026 adjusted EPS guidance is set at USD 11.60-11.75, indicating the need for newer products to continue offsetting biosimilar pressures.